Two Sigma Investments, LP Bio Atla, Inc. Transaction History

Two Sigma Investments, LP

$40.3 Billion
Q1 2024

A detailed history of Two Sigma Investments, LP transactions in Bio Atla, Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 203,089 shares of BCAB stock, worth $278,231. This represents 0.0% of its overall portfolio holdings.

Number of Shares

203,089

Previous 170,872 18.85%

Holding current value

$278,231

Previous $420,000 66.19%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.88 - $3.46 $60,567 - $111,470	32,217 Added 18.85%	203,089 $698,000
Q4 2023 Feb 14, 2024	BUY	$1.27 - $3.18 $98,525 - $246,701	77,579 Added 83.16%	170,872 $420,000
Q3 2023 Nov 14, 2023	SELL	$1.7 - $3.07 $178,834 - $322,954	-105,197 Reduced 53.0%	93,293 $158,000
Q2 2023 Aug 14, 2023	SELL	$2.83 - $3.87 $271,937 - $371,872	-96,091 Reduced 32.62%	198,490 $595,000
Q1 2023 May 15, 2023	BUY	$2.3 - $8.25 $12,854 - $46,109	5,589 Added 1.93%	294,581 $789,000

Q4 2022 Feb 14, 2023	BUY	$7.63 - $11.01 $235,530 - $339,867	30,869 Added 11.96%	288,992 $2.38 Million
Q3 2022 Nov 14, 2022	SELL	$2.94 - $11.87 $667,815 - $2.7 Million	-227,148 Reduced 46.81%	258,123 $1.99 Million
Q2 2022 Aug 15, 2022	SELL	$2.13 - $5.38 $174,988 - $441,988	-82,154 Reduced 14.48%	485,271 $1.38 Million
Q1 2022 May 16, 2022	BUY	$4.38 - $18.78 $1.69 Million - $7.26 Million	386,504 Added 213.63%	567,425 $2.84 Million
Q4 2021 Feb 14, 2022	BUY	$19.0 - $30.95 $3.44 Million - $5.6 Million	180,921 New	180,921 $3.55 Million

Others Institutions Holding BCAB

# of Institutions

Shares Held

24.8M

Call Options Held

140K

Put Options Held

4.6K

View Full List

About BioAtla, Inc.

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $49.7M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

More about BCAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.

Account

Two Sigma Investments, LP Bio Atla, Inc. Transaction History